Ozmosi | ST-1898 Drug Profile

Product Description

ST-1898 is a drug candidate being developed by Scitech Pharma, which acts as a tyrosine kinase inhibitor for the treatment of solid tumors. (Sourced from: http://www.scitech-mq.com.cn/en/contents/1115/1322.html)

Mechanisms of Action: VEGFR2 Inhibitor, C-Met Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Beijing Saite Mingqiang Pharmaceutical Technology Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ST-1898

Countries in Clinic: China

Active Clinical Trial Count: 8

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Melanoma|Renal Cell Carcinoma|Thyroid Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT07252661	ACC-1898-101	P1	Not yet recruiting	Gallbladder Cancer\|Medullary Carcinoma\|Hepatocellular Carcinoma\|Adenocarcinoma\|Gastrointestinal Cancer\|Melanoma\|Thyroid Cancer\|Renal Cell Carcinoma\|Esophageal Cancer	2027-06-01		2025-11-29
NCT06359860	ST-1898-203	P2	Recruiting	Melanoma	2026-12-01	12%	2025-08-26	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06127238	ST-1898-201	P2	Active, not recruiting	Renal Cell Carcinoma	2025-12-01	12%	2025-08-26	Primary Endpoints\|Treatments\|Trial Status
CTR20230114	CTR20230114	P2	Recruiting	Renal Cell Carcinoma	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
CTR20233031	CTR20233031	P2	Recruiting	Thyroid Cancer	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
NCT06359847	ST-1898-202	P2	Recruiting	Thyroid Cancer	2027-12-01	12%	2025-08-26	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
CTR20201808	CTR20201808	P1	Recruiting	Oncology Solid Tumor Unspecified	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
CTR20254511	CTR20254511	P1	Active, not recruiting	Oncology Solid Tumor Unspecified\|Healthy Volunteers	None		2025-12-28	Start Date\|Treatments\|Trial Status

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

ST-1898

Alternative Names: st-1898, st 1898, st1898 Clinical Status: Active Latest Update: 2025-11-28 Latest Update Note: Clinical Trial Update